http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2458818-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a708524c0adee3eb5b130dac053f9c3d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-535 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2010-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b65ace6e1a2f14af0a2e8ad7da2c2be3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_056f59b2b2d0ea5e8e19d593ff74f676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a05d19cf26e6fc9f68f5d672f3d43e21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46b146ee303d88a7e49d2de0cf42adcf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3b4fec633cf90279aec53913475bd58 |
| publicationDate | 2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2458818-T3 |
| titleOfInvention | Methods to evaluate the activity of a polysaccharide composition |
| abstract | A method of monitoring the effect of a polysaccharide preparation in an individual having cancer, the method comprising determining tumor stromal levels of myeloid-derived suppressor cells (MDSCs), endothelial progenitor cells (EPCs), expression of metallopeptidase 9 of the plasma matrix (MMP-9), granulocyte colony-stimulating factor (G-CSF) expression, interferon gamma (MIG)-induced monokine expression, or associations thereof in a sample obtained from the individual after it has been administered to the individual the polysaccharide preparation, to thereby determine the effect of the polysaccharide preparation on the individual; wherein the polysaccharide preparation has the following characteristics: a weight average chain molecular weight between 3,500 and 8,000 Da; anti-Xa activity and anti-IIa activity each less than 50 IU/mg; between 5% and 50% of uronic acid residues separated from glycol and a molecular weight distribution such that 10-50% of the oligosaccharides in the preparation have a molecular weight < 3,000 Da, 40-65% of the oligosaccharides have a molecular weight between 3,000-8,000 Da and 5-30% of the oligosaccharides have a molecular weight > 8,000 Da and in which a decrease in the level of MDSC, the level of EPC, the level of plasma MMP-9 expression, expression level of G-CSF or associations thereof relative to a reference standard indicates that the polysaccharide preparation is effective in treating cancer in the individual and a non-significant increase or change in the level of MDSCs, the EPC level, plasma MMP-9 expression level, G-CSF expression level, or associations thereof relative to a reference standard indicates that the polysaccharide preparation is not effective in treating cancer in the individual . |
| priorityDate | 2009-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 185.